Failure to Diagnose Cancer Expert Witness

Cancer delay cases are fundamentally counterfactual.

The patient has cancer now. The expert has to reconstruct what was probably true months or years earlier and answer two separate questions: should the cancer reasonably have been identified then, and would identifying it then have made a meaningful difference?

Those questions often require different experts.

A primary care physician may address whether symptoms required investigation. A radiologist may evaluate a missed lesion. A pathologist may address biopsy interpretation. An oncologist may determine whether the delay changed stage, treatment, prognosis, or survival. Related delay-of-diagnosis issues are covered on our delayed diagnosis expert witness page.

The strongest case starts by identifying exactly where the diagnostic process allegedly broke down.

Build the Timeline Backward From the Diagnosis

The eventual cancer diagnosis provides an endpoint, but the expert analysis should move backward through the record.

When was the tumor first confirmed? What did the imaging show immediately before diagnosis? Were there earlier studies? Had the patient previously reported symptoms associated with the same organ system? Was an abnormal laboratory result, screening study, mass, or other finding documented?

This chronology matters because the point at which a cancer became detectable is not necessarily the same as the point at which it first existed.

A tumor may have been biologically present long before it was large enough to identify through available testing. A reliable opinion should distinguish those concepts.

The First Missed Opportunity

Most delayed cancer cases have one or more alleged opportunities for earlier diagnosis.

A patient may report persistent symptoms that were repeatedly treated without further workup. An imaging study may contain a suspicious finding. A screening test may be abnormal. A physician may identify a mass but fail to arrange follow-up. A specialist referral may be recommended but never completed.

The expert should identify the earliest point at which the standard of care actually required something different.

That is usually more useful than listing every encounter before the diagnosis and characterizing each one as another missed opportunity.

Symptoms Do Not Diagnose Cancer

Many symptoms associated with cancer are also caused by much more common benign conditions.

Abdominal pain, cough, fatigue, weight loss, blood in the stool, urinary symptoms, headaches, anemia, back pain, or changes in bowel habits can have numerous explanations.

The standard of care generally does not require a cancer workup every time one of these symptoms appears.

The question is whether the duration, severity, associated findings, patient risk factors, or failure to improve made further investigation reasonably necessary.

Repeated symptoms can change the analysis. What was reasonable at the first visit may no longer be reasonable after the same unexplained complaint persists for months.

Screening Versus Diagnostic Testing

Cancer screening and diagnostic evaluation should not be treated as the same process.

Screening is performed in patients who may have no symptoms, such as mammography, cervical screening, colorectal screening, or selected lung cancer screening.

Diagnostic testing occurs because a symptom, examination finding, or previous test has created a specific concern.

A case involving failure to recommend routine screening raises different issues from one involving failure to investigate a palpable breast mass or unexplained gastrointestinal bleeding.

The expert should determine which clinical pathway applied to the patient at the relevant time.

Abnormal Imaging

Some of the clearest cancer delay cases involve imaging performed before the eventual diagnosis.

A CT scan may contain a pulmonary nodule. A mammogram may show an abnormality. An ultrasound may identify a mass. An earlier MRI may contain a lesion that becomes more obvious on later comparison.

The radiology expert should review the actual prior study without allowing the later diagnosis to dictate the interpretation.

Knowing where a cancer eventually appeared can make a subtle earlier finding much easier to see.

The appropriate question is whether a reasonable radiologist interpreting the original study at the original time should have recognized the finding and recommended additional evaluation.

Incidental Findings

Not every potential cancer is discovered during a test ordered to look for cancer.

A pulmonary nodule may appear on a CT obtained after trauma. A renal mass may be seen during abdominal imaging for another complaint. A lesion may be partially visible at the edge of a study focused elsewhere.

These incidental findings can create follow-up obligations depending on their size, appearance, patient risk factors, and applicable recommendations.

The expert may need to determine whether the abnormality should have been reported, whether follow-up was indicated, and which clinician was responsible for ensuring that follow-up occurred.

That last question can become complicated when several providers receive the same report.

Radiology Report Follow-Up

Sometimes the radiologist does identify the abnormality.

The failure occurs afterward.

A report may recommend repeat imaging, biopsy, specialist evaluation, or correlation with another test, but the recommendation is never completed.

The medical record should be reviewed to determine who received the report, how significant the finding was, whether the patient was notified, and what follow-up plan was documented.

The standard of care opinion should be directed at the professional whose responsibility for follow-up is actually in dispute.

It is not enough to know that a recommendation disappeared somewhere in the chart.

Laboratory Abnormalities

Cancer can also first become apparent through laboratory findings.

Persistent anemia, abnormal blood counts, elevated proteins, liver abnormalities, or other findings may eventually contribute to a diagnosis depending on the cancer involved. Related hematology issues may arise when blood abnormalities are central.

An abnormal result does not automatically require oncologic testing.

The expert should evaluate the degree of abnormality, whether it persisted, the patient's age and symptoms, competing explanations, and whether repeat testing or additional investigation was appropriate.

Trends can be more important than one isolated laboratory value.

Delayed Biopsy

Once a suspicious lesion is identified, timing of biopsy may become the central issue.

Not every abnormality requires immediate tissue diagnosis. Some findings can appropriately be monitored, while others warrant prompt biopsy or surgical evaluation.

The expert may address whether the lesion's appearance, growth, clinical setting, and applicable diagnostic pathway justified biopsy at the earlier date.

The causation analysis is separate.

Even if biopsy should have occurred months sooner, an oncologist or disease-specific specialist still has to determine whether that interval probably changed the patient's outcome.

Pathology Errors

Some cancer delays result not from failure to obtain tissue but from how the tissue was interpreted.

A biopsy may initially be read as benign, atypical, inflammatory, or otherwise nonmalignant before a later specimen establishes cancer.

A pathology expert may review the original slides and determine whether malignant features were reasonably identifiable at the time.

Later knowledge creates the same hindsight problem that exists in radiology.

The expert should interpret the earlier specimen on its own merits and explain whether the original reading fell within an acceptable diagnostic range.

Referral Delays

Cancer diagnosis often crosses multiple specialties.

A primary care physician may refer to gastroenterology, pulmonology, dermatology, urology, gynecology, surgery, or another field before oncology ever becomes involved.

A case may involve whether referral should have occurred sooner, whether an urgent referral was treated as routine, or whether abnormal findings should have been escalated when the patient could not obtain a timely appointment.

The expert evaluating the referring clinician should focus on what that clinician should reasonably have recognized.

The specialist who later diagnosed the cancer should not automatically define the standard for the earlier generalist.

Breast Cancer Delay

Breast cancer cases may involve mammography, ultrasound, MRI, palpable abnormalities, biopsy, pathology, or failure to follow an imaging recommendation. Related gynecology issues may arise depending on the care setting.

The importance of a delay depends on the biology of the tumor, not only the number of months that passed.

Hormone receptor status, HER2 status, grade, histologic type, tumor size, nodal involvement, and other characteristics may influence how quickly disease progresses and which treatments are available.

An oncologist may need to estimate the likely extent of disease at the earlier date and explain whether diagnosis then would probably have changed therapy or prognosis.

Lung Cancer Delay

Lung cancer claims frequently involve pulmonary nodules discovered on chest imaging.

The expert may evaluate nodule size, morphology, growth, smoking history, prior imaging, and whether follow-up recommendations were consistent with the patient's risk.

Serial imaging can be particularly useful because it may establish growth rate.

A lesion visible years earlier does not necessarily mean cancer could or should have been diagnosed years earlier. Small nodules often require surveillance precisely because immediate tissue diagnosis is not always appropriate.

Pulmonology, radiology, thoracic surgery, and oncology may each become relevant at different points in the case.

Colorectal Cancer Delay

Colorectal cancer cases may begin with rectal bleeding, iron-deficiency anemia, changes in bowel habits, abdominal symptoms, abnormal screening results, or an incomplete colonoscopy.

The expert may evaluate whether gastrointestinal symptoms warranted endoscopic evaluation and whether recommended screening or follow-up occurred appropriately. Related gastroenterology expertise is often central.

Once cancer is diagnosed, causation may turn on whether the disease had already spread to lymph nodes, liver, lung, or other sites before the alleged delay began.

An oncologist can then address whether earlier diagnosis would probably have altered surgical options, systemic treatment, or expected outcome.

Prostate Cancer Delay

Prostate cancer creates a particularly important distinction between diagnosis and harm.

Many prostate cancers grow slowly, and not every delay has meaningful clinical consequences.

A case may involve PSA trends, abnormal examination, MRI, biopsy decisions, pathology, or follow-up after an elevated screening result. Related urology issues often drive the standard of care analysis.

The causation expert should consider grade group, Gleason characteristics, PSA history, stage, imaging, and the natural behavior of the particular cancer.

Showing that diagnosis could have occurred earlier is not enough if the disease would probably have required the same treatment and produced the same prognosis.

Melanoma and Skin Cancer

Skin cancer cases can involve a lesion that was not biopsied, was misidentified clinically, or was misread on pathology.

For melanoma, depth and other pathologic features can have major prognostic significance.

Historical photographs may occasionally help establish how a lesion changed over time, but appearance alone may not establish when malignant transformation occurred.

Dermatology, dermatopathology, surgical oncology, and medical oncology can each play different roles depending on the allegation.

Pancreatic and Other Aggressive Cancers

Some cancers create especially difficult causation questions because they may progress rapidly and are often diagnosed at an advanced stage.

Pancreatic cancer is a common example.

An earlier diagnosis may theoretically have been possible, but the expert still must determine whether the tumor would probably have been resectable or otherwise treated differently at the alleged earlier date.

Aggressive tumor biology can narrow the difference between an earlier and later diagnosis.

This is why the phrase "six-month delay" has little meaning without understanding the particular cancer involved.

Stage Migration

One of the most important causation questions is whether the cancer changed stage during the period of alleged delay.

The expert may need to estimate whether a tumor that was metastatic at diagnosis was probably localized or regionally confined months earlier.

That analysis can involve tumor size, imaging, pathology, doubling time, known natural history, metastatic pattern, and the patient's prior studies.

Stage reconstruction is not always precise.

An expert should identify the assumptions involved and avoid claiming that an earlier stage can be known with certainty when the evidence supports only a probability.

Loss of a Surgical Option

A delay can matter even when it does not change an abstract survival percentage.

A tumor may initially have been removable and later become unresectable because of local invasion or metastatic spread.

The expert may address whether surgery would probably have been offered at the earlier point, what type of procedure would have been necessary, and what treatment became necessary after progression.

This can be especially important in cancers where surgery offers the primary opportunity for cure.

A surgical oncologist or organ-specific surgeon may be needed alongside the medical oncologist when resectability is disputed. For when that split is necessary, see when your case needs two expert witnesses.

Different Treatment Is Not Automatically Better Outcome

Earlier diagnosis may change treatment without necessarily changing prognosis.

A patient diagnosed earlier might have undergone surgery first rather than chemotherapy, received a different radiation plan, or required a less extensive procedure.

Those differences can still be relevant, but they should not be confused with proof that the patient would have survived longer.

The expert should specify the claimed consequence of delay.

Was it a lower chance of cure, a more extensive operation, additional chemotherapy, loss of organ function, or some other measurable harm?

Precision is important.

Survival Opinions

Cancer survival statistics can be powerful and easy to misuse.

Population-level survival data describes groups of patients. It does not tell us exactly how long a particular patient would have lived.

Stage is important, but age, tumor biology, treatment response, molecular characteristics, comorbidities, and other factors can also affect prognosis.

An oncology expert may use published survival information as part of the analysis, but the opinion should remain individualized to the patient's cancer.

A simplistic comparison between two stage-based survival percentages may not adequately prove what the delay caused.

Cancer Was Already Metastatic

Defense causation opinions often focus on whether metastatic disease was already present before the alleged missed opportunity.

If so, earlier diagnosis may not have changed the cancer from curable to incurable, although it could still have affected treatment or symptoms.

The expert may review earlier imaging, tumor burden at diagnosis, metastatic pattern, biology, and expected growth to assess when dissemination most likely occurred.

This can be one of the most consequential questions in the entire case.

A standard of care breach may be well supported while causation remains weak if the disease was probably already advanced.

The Problem With Doubling-Time Math

Tumor growth rates can be relevant, but cancer does not necessarily grow at a perfectly constant rate.

Working backward from the final tumor size using one assumed doubling time can create an appearance of mathematical precision that the biology does not support.

Different tumors grow at different rates, and growth may change over the course of disease.

When tumor kinetics are used, the expert should explain the medical basis for the assumptions and how much uncertainty remains.

A calculation should support the clinical evidence, not replace it.

What Earlier Diagnosis Would Actually Have Changed

This should be one of the clearest opinions in the case.

If the cancer had been diagnosed at the alleged earlier date, what probably would have happened?

Would the patient have undergone surgery? Would the operation have been less extensive? Would chemotherapy or radiation have changed? Was the disease likely curable? Would treatment have begun sooner without changing ultimate survival?

The answer should be concrete.

"Earlier diagnosis is better" is medically intuitive but legally incomplete. The expert needs to identify the specific lost treatment opportunity or additional harm caused by the delay.

Multiple Defendants and Multiple Delays

Cancer cases can involve a sequence of missed opportunities across different providers.

A primary care physician may delay referral. A radiologist may later miss a lesion. A specialist may then defer biopsy.

The expert analysis should not treat the entire period as one undifferentiated delay.

Each defendant should be evaluated based on the information available during that clinician's involvement. Causation may also differ depending on which alleged delay is assumed.

The cancer's stage may have been meaningfully different at the first missed opportunity but essentially unchanged during a much shorter later delay.

The Records That Matter Most

Prior imaging is often among the most valuable evidence because it can show whether the tumor or precursor lesion was already visible.

Primary care records, screening history, referrals, laboratory trends, specialist notes, biopsy reports, pathology slides, operative reports, staging studies, and oncology records build the rest of the chronology.

The medical record after diagnosis is important too.

Treatment response and later disease progression may provide information about the biology of the cancer that helps experts evaluate how it was likely behaving earlier.

The useful record therefore extends both before and after diagnosis.

Matching the Expert to Each Link in the Chain

Failure to diagnose cancer is rarely one expert's entire assignment.

The clinician whose earlier decision is challenged should generally be reviewed by someone practicing in the same specialty. Radiology questions belong with radiologists. Pathology interpretation belongs with pathologists. For how qualification attaches to the specific opinion, see qualifying an expert witness.

Cancer progression and the effect of delay usually require an oncologist with experience treating the particular cancer involved. Surgical questions may call for an organ-specific or oncologic surgeon.

The strongest analysis separates three questions clearly: what should have happened earlier, what the cancer probably looked like then, and what difference earlier diagnosis would probably have made. Start an expert witness search when you are ready to retain.